Combination of Biomarkers and Genetics Predicts Dementia More Accurately
Baca dalam 60 detik
- Studi terbaru menunjukkan bahwa kadar protein p-tau217 dalam darah dapat memprediksi risiko penurunan kognitif, namun maknanya berbeda tergantung varian gen APOE-ฮต4.
- Penelitian terhadap 8.582 partisipan menemukan bahwa pembawa APOE-ฮต4 mengalami percepatan penurunan kognitif 24% lebih cepat per kenaikan standar deviasi p-tau217, dibandingkan 13% pada non-pembawa.
- Pendekatan gabungan ini berpotensi meningkatkan deteksi dini demensia, tetapi masih memerlukan validasi klinis sebelum diterapkan secara rutin.
A recent study published in The Lancet Neurology reveals that combining blood biomarker measurements of p-tau217 with a person's genetic background can provide more precise predictions of who will experience faster cognitive decline. The findings offer new hope for early detection of dementia, particularly Alzheimer's, which has often been detected too late.
The study, involving 8,582 participants from the United States, Canada, and the Dominican Republic, analyzed data from various ethnic and racial groups. The average age of participants was 70 years, with 66% women and 34% men. About 47% of participants were non-Hispanic white, 16% Black, and 37% Hispanic or other ethnic groups. The researchers looked not only at whether someone experienced cognitive impairment, but also at how quickly the condition progressed.
The results showed that higher levels of p-tau217 in the blood were associated with a greater risk of cognitive impairment, both at the time of examination and during the monitoring period. However, this association was much stronger in individuals carrying the APOE-ฮต4 gene variant, long known as a genetic risk factor for Alzheimer's. In APOE-ฮต4 carriers, each one standard deviation increase in p-tau217 was associated with a 24% shorter time to cognitive impairment. In non-carriers, the reduction in time was only 13%.
"The key finding is that plasma p-tau217 appears to provide information not only about the presence of Alzheimer's-related pathology, but also about the risk and timing of cognitive impairment, and this prognostic meaning differs by APOE genotype," said Dr. Dung Trinh, an internist at MemorialCare Medical Group and Chief Medical Officer at Healthy Brain Clinic, Irvine, California, who was not involved in the study.
"In APOE-ฮต4 carriers, each 1 standard deviation increase in p-tau217 was associated with a 24% shorter time to cognitive impairment, compared with 13% in non-carriers. This pattern is consistent with the idea that APOE-ฮต4 may influence not only whether pathology develops, but also how quickly that pathology becomes symptomatic."
โ Dr. Dung Trinh, MD
The study also highlights the challenges of using blood biomarkers to estimate future cognitive health. Although p-tau217 levels can indicate the presence of Alzheimer's pathology, the same concentration does not always carry identical prognostic meaning for everyone. The researchers found that the association between p-tau217 and cognitive impairment appeared stronger in non-Hispanic white participants than in other racial and ethnic groups. However, there was no significant evidence that APOE-ฮต4 modified the association by race or ethnicity.
Limitations of the study include the use of only a single p-tau217 measurement in most of the cohort, so it could not fully assess changes in the biomarker over time. Differences in laboratory tests, clinical follow-up, and study design may also have influenced the results. In addition, the combined outcome included various types of cognitive impairment, not only Alzheimer's. Incomplete information on kidney function was also noted, as it can affect blood biomarker concentrations.
Nevertheless, the findings confirm that Alzheimer's risk is influenced by multiple factors, and interpretation of biomarker results needs to take into account an individual's genetic background. A combined approach using p-tau217 and APOE genotype could help identify those at higher risk for closer monitoring or inclusion in prevention trials.
For Indonesia, these findings open opportunities to develop more personalized early detection strategies for dementia. With a growing elderly population, the need for accurate and affordable screening tools is increasingly urgent. However, before widespread implementation, validation is needed in the Indonesian population, which has different genetic diversity and lifestyles. In addition, the readiness of laboratory infrastructure and medical personnel poses its own challenges.
Looking ahead, the question is how quickly this research can be translated into practical clinical guidance? Will the combination of biomarkers and genetics become a new standard in predicting dementia, or are larger and more diverse longitudinal studies still needed? What is clear is that the path toward more personalized treatment for Alzheimer's is increasingly open.
